Coherus Oncology, INC. (CHRS) — 8-K Filings

8-K Filings (26)

• Coherus Oncology Files 8-K with Financial Data — Nov 13, 2025 Risk: low
  On November 13, 2025, Coherus Oncology, Inc. filed an 8-K report. The filing indicates historical financial data, including details on additional paid-in capita
• Daiichi Sankyo to Acquire Coherus Oncology — Sep 8, 2025 Risk: medium
  Coherus Oncology, Inc. announced on September 5, 2025, that it has entered into a definitive agreement to be acquired by a subsidiary of Daiichi Sankyo Company,
• Coherus Oncology Faces Delisting Concerns — Jul 3, 2025 Risk: high
  Coherus Oncology, Inc. filed an 8-K on July 3, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, with the effect
• Coherus Oncology Files 8-K on Shareholder Vote Matters — Jun 13, 2025 Risk: low
  Coherus Oncology, Inc. filed an 8-K on June 13, 2025, reporting on matters submitted to a vote of security holders as of June 11, 2025. The company, formerly kn
• Coherus Oncology Files 8-K with Corporate Updates — May 30, 2025 Risk: low
  Coherus Oncology, Inc. filed an 8-K on May 29, 2025, reporting amendments to its articles of incorporation or bylaws, a Regulation FD disclosure, and financial
• Coherus BioSciences CEO Departs, New Interim Officers Appointed — Apr 25, 2025 Risk: medium
  Coherus BioSciences, Inc. announced on April 22, 2025, changes in its executive team and board. Specifically, Dennis M. Lanfear has departed as Chief Executive
• Coherus BioSciences Director Departs, Officer Compensation Noted — Apr 22, 2025 Risk: low
  Coherus BioSciences, Inc. announced on April 16, 2025, a change in its board of directors. Specifically, Dennis M. Lanfear has departed from his role as a direc
• Coherus BioSciences Completes Asset Acquisition — Apr 14, 2025 Risk: medium
  On April 11, 2025, Coherus BioSciences, Inc. announced the completion of its acquisition of certain assets from Organon & Co. This transaction involves the tran
• Coherus BioSciences Files 8-K with Material Agreement — Apr 1, 2025 Risk: medium
  On March 31, 2025, Coherus BioSciences, Inc. entered into a material definitive agreement. The company also reported other events and filed financial statements
• Coherus BioSciences Files 8-K on Security Holder Vote — Mar 13, 2025 Risk: low
  On March 11, 2025, Coherus BioSciences, Inc. filed an 8-K report indicating that it submitted matters to a vote of its security holders. The filing does not pro
• Coherus BioSciences Files 8-K on Financials — Mar 10, 2025 Risk: low
  Coherus BioSciences, Inc. filed an 8-K on March 10, 2025, reporting on its results of operations and financial condition, as well as filing financial statements
• Coherus BioSciences Relocates Principal Executive Offices — Mar 4, 2025 Risk: low
  On March 4, 2025, Coherus BioSciences, Inc. filed an 8-K report. The filing indicates a change in the company's principal executive offices to 333 Twin Dolphin
• Coherus BioSciences Files 8-K on Financials — Jan 13, 2025 Risk: low
  On January 13, 2025, Coherus BioSciences, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, a
• Coherus BioSciences Announces CEO Change and Board Refresh — Dec 4, 2024 Risk: medium
  On November 27, 2024, Coherus BioSciences, Inc. announced changes in its executive team and board of directors. Specifically, Dennis M. Lanfear has stepped down
• Coherus BioSciences Enters Material Definitive Agreement — Dec 3, 2024 Risk: medium
  On December 2, 2024, Coherus BioSciences, Inc. entered into a material definitive agreement. The filing does not disclose specific details of the agreement or a
• Daiichi Sankyo to Acquire Coherus BioSciences for $2 Billion — Sep 13, 2024 Risk: medium
  On September 13, 2024, Coherus BioSciences, Inc. announced a definitive agreement to be acquired by a subsidiary of Daiichi Sankyo Company, Limited. The transac
• Coherus BioSciences Enters Material Definitive Agreement — Jul 2, 2024 Risk: medium
  On June 27, 2024, Coherus BioSciences, Inc. entered into a Material Definitive Agreement. This agreement is related to the company's operations and is a signifi
• Coherus BioSciences Acquires Pfizer's Hulio Rights — Jun 27, 2024 Risk: medium
  On June 26, 2024, Coherus BioSciences, Inc. announced the completion of its acquisition of certain assets from Pfizer Inc., specifically related to the U.S. com
• Coherus BioSciences Announces Executive and Board Changes — Jun 5, 2024 Risk: medium
  Coherus BioSciences, Inc. announced on May 31, 2024, changes in its executive team and board of directors. Specifically, Dennis M. Lanfear has departed as CEO a
• Coherus BioSciences Reports on Shareholder Vote Matters — Jun 4, 2024 Risk: low
  Coherus BioSciences, Inc. filed an 8-K on June 4, 2024, reporting on matters submitted to a vote of security holders on May 29, 2024. The filing details the com
• Coherus BioSciences Files 8-K on Financials — Mar 13, 2024 Risk: low
  On March 13, 2024, Coherus BioSciences, Inc. filed an 8-K report detailing its financial results and operations. The filing includes information on the company'
• Coherus BioSciences Completes Pfizer Biosimilar Asset Acquisition — Mar 4, 2024 Risk: medium
  On March 1, 2024, Coherus BioSciences, Inc. announced the completion of its acquisition of certain assets related to the U.S. commercialization of biosimilar pr
• Coherus BioSciences Reports Officer/Director Changes & Compensation — Feb 22, 2024 Risk: medium
  Coherus BioSciences, Inc. filed an 8-K on February 22, 2024, reporting an event that occurred on February 20, 2024. The filing pertains to Item 5.02, specifical
• Coherus BioSciences Files 8-K on Material Agreement, Lacks Details — Feb 5, 2024
  Coherus BioSciences, Inc. filed an 8-K on February 5, 2024, to report an "Entry into a Material Definitive Agreement" and "Regulation FD Disclosure." While the
• Coherus BioSciences Reports Material Definitive Agreement — Jan 22, 2024
  Coherus BioSciences, Inc. filed an 8-K on January 22, 2024, to report an "Entry into a Material Definitive Agreement" that occurred on January 19, 2024. While t
• Coherus BioSciences Files Routine 8-K on Corporate Details — Jan 10, 2024
  This 8-K filing from Coherus BioSciences, Inc. (CHRS) on January 10, 2024, is a routine administrative filing, specifically an "Other Events" report. It confirm

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX